MedWatch

Genmab spent more than DKK 1 billion in Q1

Genmab's research and development projects have been costly in the first quarter, but the Danish biotech firm's profit has quadrupled. It maintains its guidance.

Photo: Joost Melis / Genmab / PR

The first quarter of the year has gone according to plan for the Danish biotech firm Genmab.

Research and development (R&D) activities have been especially busy, and the firm has posted a sizeable amount of money into the continued expansion of the organization.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs